CTIM-18. NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM) Article

Lassman, Andrew, Polly, Mei-Yin, Iwamoto, Fabio et al. (2023). CTIM-18. NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM) . NEURO-ONCOLOGY, 25(Supplement_5), v65-v65. 10.1093/neuonc/noad179.0258

cited authors

  • Lassman, Andrew; Polly, Mei-Yin; Iwamoto, Fabio; Sloan, Andrew; Wang, Tony; Aldape, Kenneth; Wefel, Jeffrey; Gondi, Vinai; Gutierrez, Alonson; Manasawala, Mohammed; Gilbert, Mark; Sulman, Erik; Wolchok, Jedd; Green, Richard; Neil, Elizabeth; Lukas, Rimas; Goldlust, Samuel; Snuderl, Matija; Dignam, James; Won, Minhee; Movsas, Benjamin; Mehta, Minesh

authors

publication date

  • November 10, 2023

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6.1 Pharmaceuticals
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Minority Health
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • Oxford University Press (OUP)

start page

  • v65

end page

  • v65

volume

  • 25

issue

  • Supplement_5